Interferon-λ in HCV Infection and Therapy
AbstractChronic infection with hepatitis C virus (HCV) is associated with significant liver disease and is therefore an important public health problem. The current standard-of-care therapy for chronic HCV infection consists of a combination of pegylated (PEG) interferon (IFN)-α and ribavirin. Although this therapy effectively generates a sustained viral response in approximately half of treated individuals, it is associated with significant hematological and neurological side effects. A new family of IFN-related proteins (IFN-λ1, 2, and 3; or alternately, IL-29, 28A, 28B, respectively) possesses properties that may make these cytokines superior to PEG-IFN-α for HCV therapy. Genetic studies have also implicated these proteins in both the natural and therapy-induced resolution of HCV infection. This review summarizes the basic aspects of IFN-λ biology, the potential role of these cytokines in HCV infection, and the outlook for their therapeutic application. View Full-Text
Share & Cite This Article
Pagliaccetti, N.E.; Robek, M.D. Interferon-λ in HCV Infection and Therapy . Viruses 2010, 2, 1589-1602.
Pagliaccetti NE, Robek MD. Interferon-λ in HCV Infection and Therapy . Viruses. 2010; 2(8):1589-1602.Chicago/Turabian Style
Pagliaccetti, Nicole E.; Robek, Michael D. 2010. "Interferon-λ in HCV Infection and Therapy ." Viruses 2, no. 8: 1589-1602.